Vaccines against Influenza A (H1N1) Pandemic

被引:11
|
作者
Luis Valdespino-Gomez, Jose [2 ]
Garcia-Garcia, Lourdes [1 ]
Ponce de Leon-Rosales, Samuel [2 ]
机构
[1] INSP, Cuernavaca 62508, Morelos, Mexico
[2] Lab Biol & React Mexico BIRMEX, Mexico City, DF, Mexico
关键词
Vaccines; Influenza A (H1N1); IMMUNIZATION; ANTIBODIES; SQUALENE; ILLNESS; MOTHER;
D O I
10.1016/j.arcmed.2009.10.008
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and Aims. The World Health Organization (WHO) has reported, as of September 2009, that the influenza A (H1N1) influenza pandemic has originated >300,000 laboratory-confirmed cases and 3917 deaths in 191 countries. It is recognized that pandemic vaccines have their greatest impact as a preventive strategy when administered before or near the peak incidence of cases in an outbreak. Therefore, vaccination campaigns should be in place when influenza A (H1N1) 2009 vaccines are available. We undertook this study to provide updated information on clinical evaluation of influenza A (H I NI) vaccines and review recommendations for influenza A (H1N1) vaccination campaigns and public health policy. Methods. The following methods were used: 1) review of registry at ClinicalTrials.gov. 2) search of PubMed Central (PMC) for influenza A (HIND vaccine. 3) review of recommendations of WHO, Mexican Health Secretariat (SSA) and Advisory Committee on Immunization Practices (ACIP) on influenza A (H1N1) vaccination campaigns. Results. Until October 1, 2009 there were 11 available influenza A (H1N1) candidate strains provided by WHO Global Influenza Surveillance Network. ClinicalTrials.gov registers 45 phase I and II clinical trials evaluating immunogenicity and safety of influenza A (H1N1) vaccines. Preliminary results support administration of a single dose and use of adjuvants. Main recommendations of WHO, SSA and ACIP include epidemiologic considerations, objectives, definition of target groups and reinforcement of other mitigation measures. Conclusions. The present pandemic of influenza A (HIND has shown mild to moderate severity. Vaccination strategies in Mexico will have the objective of decreasing severe outcomes, slowing transmission, protecting groups at increased risk of infection, complications, or death, and preventing overload of health services. Control of the pandemic should include reinforcement of other non-pharmacologic measures of mitigation and, importantly, an adequate strategy of social communication. (C) 2009 IMSS. Published by Elsevier Inc.
引用
收藏
页码:693 / 704
页数:12
相关论文
共 50 条
  • [11] Uptake of pandemic influenza (H1N1)-2009 vaccines in Brazil, 2010
    Domingues, Carla Magda Allan S.
    de Oliveira, Wanderson Kleber
    VACCINE, 2012, 30 (32) : 4744 - 4751
  • [12] Factors in vaccination intention against the pandemic influenza A/H1N1
    Setbon, Michel
    Raude, Jocelyn
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2010, 20 (05): : 490 - 494
  • [13] The development of vaccine viruses against pandemic A(H1N1) influenza
    Robertson, James S.
    Nicolson, Carolyn
    Harvey, Ruth
    Johnson, Rachel
    Major, Diane
    Guilfoyle, Kate
    Roseby, Sarah
    Newman, Robert
    Collin, Rebecca
    Wallis, Chantal
    Engelhardt, Othmar G.
    Wood, John M.
    Le, Jianhua
    Manojkumar, Ramanunninair
    Pokorny, Barbara A.
    Silverman, Jeanmarie
    Devis, Rene
    Bucher, Doris
    Verity, Erin
    Agius, Catherine
    Camuglia, Sarina
    Ong, Chi
    Rockman, Steven
    Curtis, Anne
    Schoofs, Peter
    Zoueva, Olga
    Xie, Hang
    Li, Xing
    Lin, Zhengshi
    Ye, Zhiping
    Chen, Li-Mei
    O'Neill, Eduardo
    Balishe, Amanda
    Lipatov, Aleksandr S.
    Guo, Zhu
    Isakova, Irina
    Davis, Charles T.
    Rivailler, Pierre
    Gustin, Kortney M.
    Belser, Jessica A.
    Maines, Taronna R.
    Tumpey, Terrence M.
    Xu, Xiyan
    Katz, Jacqueline M.
    Klimov, Alexander
    Cox, Nancy J.
    Donis, Ruben O.
    VACCINE, 2011, 29 (09) : 1836 - 1843
  • [14] Effectiveness of the 2009 Pandemic H1N1 Influenza Vaccines in Preventing H1N1 Infection: A Meta-Analysis
    Bozat-Emre, Songul
    Ye, Xibiao
    Morrow, Adrienne
    Casaclang, Natalie
    Mahmud, Salaheddin M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 161 - 162
  • [15] Effectiveness of seasonal influenza vaccines against influenza A (H1N1) infection in post-pandemic seasons: a systematic review
    Bozat-Emre, Songul
    Casaclang, Natalie
    Sinnock, Hasantha C.
    Ye, Xibiao
    Mahmud, Salaheddin M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 178 - 179
  • [16] Advances in protein subunit vaccines against H1N1/09 influenza
    Zhang, Yu
    Gao, Jingyao
    Xu, Wenqi
    Huo, Xingyu
    Wang, Jingyan
    Xu, Yirui
    Ding, Wenting
    Guo, Zeliang
    Liu, Rongzeng
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [17] 2009 Influenza A (H1N1) Pandemic
    Kumate Rodriguez, Jesus
    CIRUGIA Y CIRUJANOS, 2009, 77 (03): : 157 - 158
  • [18] Preparation for a pandemic: influenza A H1N1
    Shetty, Priya
    LANCET INFECTIOUS DISEASES, 2009, 9 (06): : 339 - 340
  • [19] The Pandemic H1N1 Influenza Experience
    Richt, Juergen A.
    Webby, Richard J.
    Kahn, Robert E.
    ONE HEALTH: THE HUMAN-ANIMAL-ENVIRONMENT INTERFACES IN EMERGING INFECTIOUS DISEASES: THE CONCEPT AND EXAMPLES OF A ONE HEALTH APPROACH, 2013, 365 : 269 - 279
  • [20] Pediatrics Pandemic Influenza A (H1N1)
    Ozdemir, Halil
    Ciftci, Ergin
    JOURNAL OF PEDIATRIC INFECTION, 2013, 7 (01): : 45 - 46